8-K



 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 3, 2015
 
 
GLOBUS MEDICAL, INC.
(Exact name of registrant as specified in charter)
 
 
 
 
 
 
 
 
DELAWARE
 
001-35621
 
04-3744954
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403
(Address of principal executive offices) (Zip Code)
(610) 930-1800
(Registrant's telephone number, including area code)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))






Item 2.02. Results of Operations and Financial Condition.
On November 3, 2015 we issued a press release reporting, among other things, our sales and operating results for the three- and nine- month periods ended September 30, 2015. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated by reference into this Item 2.02 as is fully set forth herein.
In accordance with general instruction B.2 to Form 8-K, the information included in this Item 2.02, and the exhibits attached hereto, shall be deemed to be “furnished” and shall not be deemed to be “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
Item 9.01. Financial Statements and Exhibits.
Exhibit No.
Description
 
 
99.1
Press Release dated November 3, 2015
 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 
 
GLOBUS MEDICAL, INC.
 
 
(Registrant)
 
 
 
Dated:
November 3, 2015
/s/ DANIEL T. SCAVILLA
 
 
 
 
 
Daniel T. Scavilla
 
 
Senior Vice President,
 
 
Chief Financial Officer


EXHIBIT LIST
Exhibit No.
Description
 
 
99.1
Press Release dated November 3, 2015




Exhibit


Exhibit 99.1


Globus Medical Reports Third Quarter 2015 Results
Reports Record Quarterly Sales and Increases Guidance

AUDUBON, PA, November 3, 2015: Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal implant manufacturer, today announced its financial results for the third quarter ended September 30, 2015.

Worldwide sales increased 16.3% to $137.0 million, or 17.6% on a constant currency basis
Third quarter net income increased 14.8% to $26.5 million, or 18.0% on a constant currency basis
Fully diluted earnings per share (EPS) were $0.28
Non-GAAP Adjusted EBITDA was 36.9% of sales
Company increases 2015 guidance for sales to $539 million and EPS to $1.07

David Paul, Chairman and CEO said, “We are pleased to report third quarter sales of $137 million, a year-over-year increase of 16.3% as reported and 17.6% on a constant currency basis. Once again the Globus team achieved strong sales growth and market share gains while maintaining industry leading profitability, with quarterly net income of $26.5 million, or 14.8% higher than the same quarter last year. During the third quarter, we also launched 3 new products and made further progress on integrating our two most recent acquisitions. We remain confident in our long term growth prospects and our ability to sustain our industry leading profitability by the continued execution of our strategy of introducing innovative products, expanding our U.S. and international sales footprint, and controlling our expenses.”

Third quarter sales in the U.S. grew by 17.9% over the third quarter of 2014. International sales increased by 1.2% over the third quarter of 2014 on an as reported basis and 14.6% on a constant currency basis.

Third quarter net income was $26.5 million, an increase of 14.8%, or 18.0% on a constant currency basis. Fully diluted EPS for the third quarter was $0.28, as compared to $0.24 for the third quarter 2014.

Cash, cash equivalents and marketable securities ended the quarter at $300.1 million. The company remains debt free.

2015 Annual Guidance
The company today increased guidance for full year 2015 sales by $15 million to $539 million and earnings per share by $0.03 to $1.07. The increased sales guidance takes into account our expectations for $5.5 million unfavorable impact of foreign currency exchange.



Conference Call Information
Globus Medical will hold a teleconference to discuss its 2015 third quarter results with the investment community at 5:30 p.m. Eastern Time today. Globus invites all interested parties to join the call by dialing:
 
1-855-533-7141     United States Participants
1-720-545-0060     International Participants
There is no pass code for the teleconference.

For interested parties who do not wish to ask questions, the teleconference will be webcast live and may be accessed through a link on the Globus Medical website at investors.globusmedical.com.






If you are unable to participate during the live teleconference, the call will be archived until Tuesday, November 17, 2015. The audio archive can be accessed by calling 1-855-859-2056 in the U.S. or 1-404-537-3406 from outside the U.S. The passcode for the audio replay is 8132-2678.


About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal implant company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders.


Non-GAAP Financial Measures
To supplement our financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), management uses certain non-GAAP financial measures. For example, Adjusted EBITDA, which represents net income before interest income, net and other non-operating expenses, provision for income taxes, depreciation and amortization, stock-based compensation, changes in the fair value of contingent consideration in connection with business acquisitions and other acquisition related costs, and provisions for litigation, is useful as an additional measure of operating performance, and particularly as a measure of comparative operating performance from period to period, as it is reflective of changes in pricing decisions, cost controls and other factors that affect operating performance, and it removes the effect of our capital structure, asset base, income taxes and interest income and expense. Our management also uses Adjusted EBITDA for planning purposes, including the preparation of our annual operating budget and financial projections. In addition, for the periods ended September 30, 2015 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP diluted earnings per share, which represent net income and diluted earnings per share, respectively, before provisions for litigation, net of the tax effects of such provisions. We believe these non-GAAP measures are also useful indicators of our operating performance, and particularly as additional measures of comparative operative performance from period to period as they remove the effects of litigation, which we believe are not reflective of underlying business trends. We also define the non-GAAP measure of Free Cash Flow as the net cash provided by operating activities, adjusted for the impact of restricted cash, less the cash impact of purchases of property and equipment. We believe that this financial measure provides meaningful information for evaluating our overall financial performance for comparative periods as it facilitates an assessment of funds available to satisfy current and future obligations and fund acquisitions. Furthermore, we define the non-GAAP measure of sales and net income on a constant currency basis as the current and prior period sales and net income translated at the same predetermined exchange rate. We believe that sales and net income on a constant currency basis provides insight to the comparative increase or decrease in period sales and net income, in dollar and percentage terms, excluding the effects of fluctuations in foreign currency exchange rates.

Adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, Free Cash Flow and sales and net income on a constant currency basis are not calculated in conformity with U.S. GAAP. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for financial measures prepared in accordance with U.S. GAAP. These measures do not include





certain expenses that may be necessary to evaluate our liquidity or operating results. Our definitions of Adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, Free Cash Flow, and sales and net income on a constant currency basis may differ from that of other companies and therefore may not be comparable.

Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.






GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(unaudited)

 
Three Months Ended
 
Nine Months Ended
(In thousands, except per share amounts)
September 30,
2015
 
September 30,
2014
 
September 30,
2015
 
September 30,
2014
Sales
$
136,992

 
$
117,787

 
$
402,166

 
$
345,570

Cost of goods sold
33,052

 
27,686

 
97,738

 
79,581

Gross profit
103,940

 
90,101

 
304,428

 
265,989

 
 
 
 
 
 
 
 
 Operating expenses:
 
 
 
 
 
 
 
Research and development
9,409

 
8,146

 
27,146

 
23,283

Selling, general and administrative
53,829

 
46,986

 
160,624

 
140,089

Provision for litigation
27

 
46

 
433

 
3,899

Total operating expenses
63,265

 
55,178

 
188,203

 
167,271

 
 
 
 
 
 
 
 
Operating income
40,675

 
34,923

 
116,225

 
98,718

Other income/(expense), net
253

 
(124
)
 
347

 
446

Income before income taxes
40,928

 
34,799

 
116,572

 
99,164

Income tax provision
14,447

 
11,738

 
41,389

 
34,317

 
 
 
 
 
 
 
 
Net income
$
26,481

 
$
23,061

 
$
75,183

 
$
64,847

 
 
 
 
 
 
 
 
Earnings per share:
 
 
 
 
 
 
 
Basic
$
0.28

 
$
0.24

 
$
0.79

 
$
0.69

Diluted
$
0.28

 
$
0.24

 
$
0.78

 
$
0.68

Weighted average shares outstanding:
 
 
 
 
 
 
 
Basic
95,138

 
94,399

 
94,970

 
94,111

Diluted
96,119

 
95,475

 
96,026

 
95,378






GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

(In thousands, except par value)
September 30,
2015
 
December 31, 2014
 
(unaudited)
 
 
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
50,501

 
$
82,265

Restricted cash
25,385

 
23,370

Short-term marketable securities
188,101

 
146,439

Accounts receivable, net of allowances of $2,224 and $1,647, respectively
77,596

 
75,430

Inventories
105,705

 
90,945

Prepaid expenses and other current assets
7,107

 
5,742

Income taxes receivable
7,995

 
5,772

Deferred income taxes
43,918

 
40,062

Total current assets
506,308

 
470,025

Property and equipment, net of accumulated depreciation of $134,108 and $118,544, respectively
106,180

 
69,475

Long-term marketable securities
61,525

 
75,347

Intangible assets, net
33,635

 
34,529

Goodwill
91,964

 
53,196

Other assets
1,049

 
975

Total assets
$
800,661

 
$
703,547

 
 
 
 
LIABILITIES AND EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
16,358

 
$
15,904

Accounts payable to related-party

 
5,359

Accrued expenses
64,169

 
61,499

Income taxes payable
550

 
569

Business acquisition liabilities, current
13,342

 
6,081

Total current liabilities
94,419

 
89,412

Business acquisition liabilities, net of current portion
20,732

 
20,195

Deferred income taxes
8,193

 
5,166

Other liabilities
3,400

 
3,320

Total liabilities
126,744

 
118,093

Commitments and contingencies
 
 
 
Equity:
 
 
 
Common stock; $0.001 par value. Authorized 785,000 shares; issued and outstanding 95,226 and 94,706 shares at September 30, 2015 and December 31, 2014, respectively
95

 
95

Additional paid-in capital
188,603

 
175,242

Accumulated other comprehensive loss
(1,738
)
 
(1,657
)
Retained earnings
486,957

 
411,774

Total equity
673,917

 
585,454

Total liabilities and equity
$
800,661

 
$
703,547






GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
 
Nine Months Ended
(In thousands)
September 30,
2015
 
September 30,
2014
Cash flows from operating activities:
 
 
 
Net income
$
75,183

 
$
64,847

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Depreciation and amortization
17,669

 
16,057

Amortization of premium on marketable securities
2,352

 
2,073

Write-down for excess and obsolete inventories
7,122

 
5,439

Stock-based compensation expense
6,935

 
5,211

Excess tax benefit related to nonqualified stock options
(1,973
)
 
(4,044
)
Allowance for doubtful accounts
957

 
236

Change in deferred income taxes
(4,115
)
 
(5,115
)
Increase in:
 
 
 
Restricted cash
(2,015
)
 

Accounts receivable
(3,468
)
 
(886
)
Inventories
(16,998
)
 
(12,535
)
Prepaid expenses and other assets
(1,368
)
 
(1,325
)
Increase/(decrease) in:
 
 
 
Accounts payable
(2,812
)
 
(2,253
)
Accounts payable to related-party
(5,359
)
 
1,289

Accrued expenses and other liabilities
6,042

 
3,855

Income taxes payable/receivable
(275
)
 
4,378

Net cash provided by operating activities
77,877

 
77,227

 
 
 
 
Cash flows from investing activities:
 
 
 
Purchases of marketable securities
(207,407
)
 
(161,149
)
Maturities of marketable securities
131,318

 
144,207

Sales of marketable securities
46,064

 
24,028

Purchases of property and equipment
(36,606
)
 
(15,659
)
Acquisition of businesses, net of cash acquired
(48,513
)
 

Net cash used in investing activities
(115,144
)
 
(8,573
)
 
 
 
 
Cash flows from financing activities:
 
 
 
Payment of business acquisition liabilities
(900
)
 
(900
)
Proceeds from exercise of stock options
4,313

 
7,644

Excess tax benefit related to nonqualified stock options
1,973

 
4,044

Net cash provided by financing activities
5,386

 
10,788

 
 
 
 
Effect of foreign exchange rate on cash
117

 
45

 
 
 
 
Net increase/(decrease) in cash and cash equivalents
(31,764
)
 
79,487

Cash and cash equivalents, beginning of period
82,265

 
89,962

Cash and cash equivalents, end of period
$
50,501

 
$
169,449

 
 
 
 
Supplemental disclosures of cash flow information:
 
 
 
Interest paid
9

 
32

Income taxes paid
$
45,955

 
$
36,362







Supplemental Financial Information

Sales by Geographic Area:
(Unaudited)
Three Months Ended
 
Nine Months Ended
(In thousands)
September 30,
2015
 
September 30,
2014
 
September 30,
2015
 
September 30,
2014
United States
$
125,670

 
$
106,601

 
$
367,140

 
$
309,937

International
11,322

 
11,186

 
35,026

 
35,633

Total sales
$
136,992

 
$
117,787

 
$
402,166

 
$
345,570

 
Sales by Product Category:
(Unaudited)
Three Months Ended
 
Nine Months Ended
(In thousands)
September 30,
2015
 
September 30,
2014
 
September 30,
2015
 
September 30,
2014
Innovative Fusion
$
72,490

 
$
67,726

 
$
214,431

 
$
200,356

Disruptive Technology
64,502

 
50,061

 
187,735

 
145,214

Total sales
$
136,992

 
$
117,787

 
$
402,166

 
$
345,570

Liquidity and Capital Resources:
(Unaudited)
September 30,
2015
 
December 31,
2014
(In thousands)
 
 
 
Cash and cash equivalents
$
50,501

 
$
82,265

Short-term marketable securities
188,101

 
146,439

Long-term marketable securities
61,525

 
75,347

Total cash, cash equivalents and marketable securities
$
300,127

 
$
304,051

 
 
 
 
Available borrowing capacity under revolving credit facility
50,000

 
50,000

Working capital
$
411,889

 
$
380,613

The following tables reconcile GAAP to Non-GAAP financial measures.
Non-GAAP Adjusted EBITDA Reconciliation Table:
(Unaudited)
Three Months Ended
 
Nine Months Ended
(In thousands, except percentages)
September 30,
2015
 
September 30,
2014
 
September 30,
2015
 
September 30,
2014
Net income
$
26,481

 
$
23,061

 
$
75,183

 
$
64,847

Interest income, net
(342
)
 
(181
)
 
(898
)
 
(577
)
Provision for income taxes
14,447

 
11,738

 
41,389

 
34,317

Depreciation and amortization
6,090

 
5,373

 
17,669

 
16,057

EBITDA
46,676

 
39,991

 
133,343

 
114,644

Stock-based compensation expense
2,266

 
1,661

 
6,935

 
5,211

Provision for litigation
27

 
46

 
433

 
3,899

Change in fair value of contingent consideration and other acquisition related costs
1,550

 
263

 
2,864

 
416

Adjusted EBITDA
$
50,519

 
$
41,961

 
$
143,575

 
$
124,170

Adjusted EBITDA as a percentage of sales
36.9
%
 
35.6
%
 
35.7
%
 
35.9
%





Non-GAAP Net Income Reconciliation Table:
(Unaudited)
Three Months Ended
 
Nine Months Ended
(In thousands)
September 30,
2015
 
September 30,
2014
 
September 30,
2015
 
September 30,
2014
Net income
$
26,481

 
$
23,061

 
$
75,183

 
$
64,847

Provision for litigation, net of taxes
18

 
30

 
279

 
2,527

Non-GAAP net income
$
26,499

 
$
23,091

 
$
75,462

 
$
67,374

Non-GAAP Diluted Earnings Per Share Reconciliation Table:
(Unaudited)
Three Months Ended
 
Nine Months Ended
(Per share amounts)
September 30,
2015
 
September 30,
2014
 
September 30,
2015
 
September 30,
2014
Diluted earnings per share, as reported
$
0.28

 
$
0.24

 
$
0.78

 
$
0.68

Provision for litigation, net of taxes

 

 
0.01

 
0.03

Non-GAAP diluted earnings per share
$
0.28

 
$
0.24

 
$
0.79

 
$
0.71

Non-GAAP Free Cash Flow Reconciliation Table:
(Unaudited)
Three Months Ended
 
Nine Months Ended
(In thousands)
September 30,
2015
 
September 30,
2014
 
September 30,
2015
 
September 30,
2014
Net cash provided by operating activities
$
30,046

 
$
35,645

 
$
77,877

 
$
77,227

Adjustment for impact of restricted cash
703

 

 
2,015

 

Purchases of property and equipment
(11,480
)
 
(3,428
)
 
(36,606
)
 
(15,659
)
Non-GAAP free cash flow
$
19,269

 
$
32,217

 
$
43,286

 
$
61,568

Non-GAAP Sales and Net Income on a Constant Currency Basis Comparative Table:
(Unaudited)
Three Months Ended
 
Percent Change
(In thousands, except percentages)
September 30,
2015
 
September 30,
2014
 
Reported
 
Constant Currency
United States
$
125,670

 
$
106,601

 
17.9
%
 
17.9
%
International
11,322

 
11,186

 
1.2
%
 
14.6
%
Total sales
$
136,992

 
$
117,787

 
16.3
%
 
17.6
%
 
 
 
 
 
 
 
 
Net Income
$
26,481

 
$
23,061

 
14.8
%
 
18.0
%
(Unaudited)
Nine Months Ended
 
Percent Change
(In thousands, except percentages)
September 30,
2015
 
September 30,
2014
 
Reported
 
Constant Currency
United States
$
367,140

 
$
309,937

 
18.5
 %
 
18.5
%
International
35,026

 
35,633

 
(1.7
%)
 
11.0
%
Total sales
$
402,166

 
$
345,570

 
16.4
 %
 
17.7
%
 
 
 
 
 
 
 
 
Net Income
$
75,183

 
$
64,847

 
15.9
 %
 
18.4
%






Contact:
Daniel Scavilla
Senior Vice President, Chief Financial Officer
Phone: (610) 930-1800
Email:     investors@globusmedical.com
www.globusmedical.com